BACKGROUND: There has been no consensus about selection and application dosage of immunosuppressive drugs after kidney transplantation due to great individual difference of drugs caused by gradual development and application.
OBJECTIVE: To explore the immunosuppressive efficacy, the protective effects on renal function and the application safety of the quadruple immunosuppressive therapy based on low dosage of Tacrolimus (Tac) in kidney transplantation.
METHODS: In the control group (schedule 1), Tac, mycophenolate mofetil (MMF), and prednisone were used. In the experimental group 1, reduced dose of Tac and MMF (schedule 2) and sirolimus (SRL) were used. In the experimental group 2, reduced dose of Tac and MMF (schedule 2) and mizoribine (MZR) were used. The recipient lymphocyte reaction in each group was detected at 2, 4 weeks, 6 months and 1 year after surgery. Urine transforming growth factor -β1 was tested once every 6 months. Liver and renal function, blood and urine routine, and blood glucose were examined every 1-3 months after kidney transplantation. All patients were followed up for 4 years.
RESULTS AND CONCLUSION: There was no significant difference in acute rejection and infection rate among the three groups. At 4 weeks after transplantation, the recipient lymphocyte reaction was significantly weaker in the experimental groups 1, 2 than in the control group (P < 0.05). At 1 year after transplantation, transforming growth factor β1 concentration was significantly lower in the experimental groups 1, 2 than in the control group (P < 0.05). At 2 years after transplantation, serum creatinine and creatinine clearance rate were significantly lower, and adverse events including liver damage and high glucose, were fewer in the experimental groups 1, 2 than in the control group (P < 0.05). These findings suggest that compared with the triple immunosuppressive therapy based on conventional dose of Tac, the quadruple immunosuppressive therapy shares the same immunosuppressive efficacy with fewer side effects and less nephrotoxicity and liver function impairment as well as slower renal fibrosis process, which may benefit the long-term survival of renal grafts.